- Galleri revenue rose 14% YoY to $37.3M with test volumes up 24% to >56k, supported by a positive FDA advisory panel vote.
- Net loss widened by 16% YoY to $103.6M ($2.21 per share) while adjusted gross margin contracted to 42% from 55%.
- Cash and cash equivalents decreased severely from $249.7M at year-end 2025 to $29.0M at quarter-end, heightening dilution risk.
Signal #134483 · SEC 8-K
$GRAL SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $GRAL filing catalyst
Why did $GRAL trigger an AI stock catalyst alert?
$GRAL triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -4.5/10). Headline: GRAIL Reports Q3 2026: Revenue Up 14% to $37.3M, Net Loss Expands to $103.6M as Cash Drops to $29M. Key points: - Galleri revenue rose 14% YoY to $37.3M with test volumes up 24% to >56k, supported by a positive FDA advisory panel vote. - Net loss widened by 16% YoY to $103.6M ($2.21 per share) while adjusted gross margin contracted to 42% from 55%. - Cash and cash equivalents decreased severely from $249.7M at year-end 2025 to $29.0M at quarter-end, heightening dilution risk.
How did $GRAL stock react after the SEC filing?
After the SEC 8-K for $GRAL, observed market reaction: T0 price $143.66. Past moves do not guarantee future results.
Where can I get real-time $GRAL SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $GRAL via Telegram and the VIP Web Terminal from €10/month.